{"id":49185,"date":"2022-05-11T17:46:29","date_gmt":"2022-05-11T16:46:29","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&#038;p=49185"},"modified":"2023-05-17T16:52:32","modified_gmt":"2023-05-17T15:52:32","slug":"ruth-perets-aacr-2022-vibostolimab-pembrolizumab-coformulation-for-the-treatment-of-ovarian-cancer-naive-to-pd-1-pd-l1-inhibitors","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/ovarian-cancer\/conference-hub\/ruth-perets-aacr-2022-vibostolimab-pembrolizumab-coformulation-for-the-treatment-of-ovarian-cancer-naive-to-pd-1-pd-l1-inhibitors\/","title":{"rendered":"Ruth Perets, AACR 2022: Vibostolimab \/ Pembrolizumab Coformulation for the Treatment of Ovarian Cancer Naive to PD-1\/PD-L1 Inhibitors"},"content":{"rendered":"<p>We were delighted to speak with <strong>Dr. Ruth Perets<\/strong> (Rambam Health Care Campus, Haifa, Israel) about the efficacy and safety findings of the phase 1 study comparing vibostolimab (vibo) plus pembrolizumab (pembro) given sequentially to the coformulation of vibo\/pembro in ovarian cancer naive to PD-1\/PD-L1 inhibitors.<\/p>\n<p>The abstract \u2018<em>Safety and efficacy of vibostolimab (vibo) plus pembrolizumab (pembro) and coformulation of vibo\/pembro in ovarian cancer naive to PD-1\/PD-L1 inhibitors.<\/em>\u2019 (Abstract number CT180) was presented at AACR 2022, 8-13 April, 2022.<\/p>\n<p><strong>Questions<\/strong><\/p>\n<ol>\n<li>What are the current unmet needs in the treatment of ovarian cancer in patients who are naive to PD-1\/PD-L1 inhibitors? (0:30)<\/li>\n<li>What is the potential role of the anti-TIGIT antibody vibostolimab in ovarian cancer management? (1:19)<\/li>\n<li>How might the efficacy of vibostolimab differ if used in combination with pembrolizumab compared with as a coformulation with pembrolizumab? (2:28)<\/li>\n<li>What are the current findings of this ongoing phase 1 study of the vibostolimab\/ pembrolizumab coformulation? (3:08)<\/li>\n<\/ol>\n<p><strong>Disclosures:<\/strong> Ruth Perets discloses consulting for MSD.<\/p>\n<p><strong>Support:<\/strong> Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.<\/p>\n<p><strong><em>Filmed in coverage of the AACR annual meeting 2022.<\/em><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>We were delighted to speak with Dr. Ruth Perets (Rambam Health Care Campus, Haifa, Israel) about the efficacy and safety findings of the phase 1 study comparing vibostolimab (vibo) plus pembrolizumab (pembro) given sequentially to the coformulation of vibo\/pembro in ovarian cancer naive to PD-1\/PD-L1 inhibitors. The abstract \u2018Safety and efficacy of vibostolimab (vibo) plus [&hellip;]<\/p>\n","protected":false},"featured_media":49186,"template":"","class_list":["post-49185","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-ovarian-cancer","video_categories-aacr-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/49185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":5,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/49185\/revisions"}],"predecessor-version":[{"id":74997,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media_gallery\/49185\/revisions\/74997"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media\/49186"}],"wp:attachment":[{"href":"https:\/\/touchoncology.com\/wp-json\/wp\/v2\/media?parent=49185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}